Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIND-014 in advanced solid tumors (iNSITE 2)
NCT02479178Phase 2Terminated
- Sponsor
- BIND Therapeutics
- Start
- Jun 2015
- Primary completion
- Oct 2016
- Modality
- Nanoparticles
- Countries
- 2
01
Overview
A Phase 2 trial of BIND-014 in urothelial carcinoma (UC), Cervical Cancer (CC), cholangiocarcinoma (CCA), biliary tract cancer (BTC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by BIND Therapeutics. Started Jun 2015; status: terminated.
02
Drugs
BIND-014
03
Conditions
urothelial carcinoma (UC)Cervical Cancer (CC)cholangiocarcinoma (CCA)biliary tract cancer (BTC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02479178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479178.